|
1
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al; European Organisation for Research and Treatment
of Cancer Brain Tumour and Radiation Oncology Groups; National
Cancer Institute of Canada Clinical Trials Group. Effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yuki K, Natsume A, Yokoyama H, Kondo Y,
Ohno M, Kato T, Chansakul P, Ito M, Kim SU and Wakabayashi T:
Induction of oligodendrogenesis in glioblastoma-initiating cells by
IFN-mediated activation of STAT3 signaling. Cancer Lett. 284:71–79.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
4
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H,
Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene
expression and chemoresistance of CD133+ cancer stem
cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar
|
|
7
|
Zhao Y, Huang Q, Zhang T, Dong J, Wang A,
Lan Q, Gu X and Qin Z: Ultrastructural studies of glioma stem
cells/progenitor cells. Ultrastruct Pathol. 32:241–245. 2008.
View Article : Google Scholar
|
|
8
|
Yang B, Wang Y, Yang C, Ouyang W, Zhou F,
Zhou Y and Xie C: The ultrastructural difference between
CD133-positive U251 glioma stem cells and normal U251 glioma cells.
Ultrastruct Pathol. 36:404–408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Natsume A, Kato T, Kinjo S, Enomoto A,
Toda H, Shimato S, Ohka F, Motomura K, Kondo Y, Miyata T, et al:
Girdin maintains the stemness of glioblastoma stem cells. Oncogene.
31:2715–2724. 2012. View Article : Google Scholar
|
|
10
|
Yoshino A, Ogino A, Yachi K, Ohta T,
Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E,
et al: Gene expression profiling predicts response to temozolomide
in malignant gliomas. Int J Oncol. 36:1367–1377. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He J, Shan Z, Li L, Liu F, Liu Z, Song M
and Zhu H: Expression of glioma stem cell marker CD133 and
O6-methylguanine-DNA methyltransferase is associated
with resistance to radiotherapy in gliomas. Oncol Rep.
26:1305–1313. 2011.PubMed/NCBI
|
|
12
|
Vescovi AL, Galli R and Reynolds BA: Brain
tumour stem cells. Nat Rev Cancer. 6:425–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Clevers H: The cancer stem cell: Premises,
promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim KJ, Lee KH, Kim HS, Moon KS, Jung TY,
Jung S and Lee MC: The presence of stem cell marker-expressing
cells is not prognostically significant in glioblastomas.
Neuropathology. 31:494–502. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Villalva C, Cortes U, Wager M, Tourani JM,
Rivet P, Marquant C, Martin S, Turhan AG and Karayan-Tapon L:
O6-Methylguanine-methyltransferase (MGMT) promoter
methylation status in glioma stem-like cells is correlated to
temozolomide sensitivity under differentiation-promoting
conditions. Int J Mol Sci. 13:6983–6994. 2012. View Article : Google Scholar
|
|
17
|
Dimov I, Tasić-Dimov D, Conić I and
Stefanovic V: Glioblastoma multiforme stem cells. Sci World J.
11:930–958. 2011. View Article : Google Scholar
|
|
18
|
Jin X, Jin X, Jung JE, Beck S and Kim H:
Cell surface Nestin is a biomarker for glioma stem cells. Biochem
Biophys Res Commun. 433:496–501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Beier D, Hau P, Proescholdt M, Lohmeier A,
Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier
CP: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells
show differential growth characteristics and molecular profiles.
Cancer Res. 67:4010–4015. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeppernick F, Ahmadi R, Campos B, Dictus
C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B and
Herold-Mende CC: Stem cell marker CD133 affects clinical outcome in
glioma patients. Clin Cancer Res. 14:123–129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pavon LF, Marti LC, Sibov TT, Malheiros
SM, Oliveira DM, Guilhen DD, Camargo-Mathias MI, Amaro Junior E and
Gamarra LF: The ultrastructural study of tumorigenic cells using
nanobiomarkers. Cancer Biother Radiopharm. 25:289–298. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mao XG, Zhang X, Xue XY, Guo G, Wang P,
Zhang W, Fei Z, Zhen HN, You SW and Yang H: Brain tumor stem-like
cells identified by neural stem cell marker CD15. Transl Oncol.
2:247–257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Capela A and Temple S: LeX/ssea-1 is
expressed by adult mouse CNS stem cells, identifying them as
nonependymal. Neuron. 35:865–875. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Son MJ, Woolard K, Nam DH, Lee J and Fine
HA: SSEA-1 is an enrichment marker for tumor-initiating cells in
human glioblastoma. Cell Stem Cell. 4:440–452. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang QB, Ji XY, Huang Q, Dong J, Zhu YD
and Lan Q: Differentiation profile of brain tumor stem cells: A
comparative study with neural stem cells. Cell Res. 16:909–915.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lobo MV, Alonso FJ, Redondo C,
López-Toledano MA, Caso E, Herranz AS, Paíno CL, Reimers D and
Bazán E: Cellular characterization of epidermal growth
factor-expanded free-floating neurospheres. J Histochem Cytochem.
51:89–103. 2003. View Article : Google Scholar
|
|
27
|
Arum CJ, Anderssen E, Viset T, Kodama Y,
Lundgren S, Chen D and Zhao CM: Cancer immunoediting from
immunosurveillance to tumor escape in microvillus-formed niche: A
study of syngeneic orthotopic rat bladder cancer model in
comparison with human bladder cancer. Neoplasia. 12:434–442. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zaguia F and Schneider R: Microvilli
expressed on glioma cells keep cytotoxic cells at a distance.
Cancer Biol Ther. 11:1–3. 2011. View Article : Google Scholar
|
|
29
|
Gritti A, Vescovi AL and Galli R: Adult
neural stem cells: Plasticity and developmental potential. J
Physiol Paris. 96:81–90. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eramo A, Ricci-Vitiani L, Zeuner A,
Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C and
De Maria R: Chemotherapy resistance of glioblastoma stem cells.
Cell Death Differ. 13:1238–1241. 2006. View Article : Google Scholar : PubMed/NCBI
|
